The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.

Attovia Therapeutics and Braveheart Bio revealed on Tuesday plans to go public, where they’ll aim to add to a recent upswing in big-ticket biotechnology stock offerings. Behind that prospect are two ...

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, ...

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing. But that relationship has deteriorated since then. ATP sued ...

NextCure became a target following research setbacks and a decision to layoff a chunk of its staff in 2024, a restructuring that funded its operations through 2026. After the transaction closes, its ...

Detailed findings from a closely watched clinical trial hint that a new kind of drug may offer similar benefits as approved medicines in early Alzheimer’s disease, a result that could boost the ...

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that ...

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...